Pancreatic Cancer Research

ResearcherUniversity of Colorado AnschutzActive in the last 2 years

Martin D. McCarter

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8174-1713; OpenAlex author ID A5036784999. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
65
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: 3 papers · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper

Papers 9

  1. Gaining a new angle on pancreas cancer: A pre-operative thrombelastographic parameter predicts recurrence and survival among patients with resected periampulla… Co-author DOI 10.1016/j.amjsurg.2024.115820↗
  2. Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreati… Co-author DOI 10.1016/j.hpb.2020.11.004↗
  3. Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-3892↗
  4. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  5. Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pan… Last author DOI 10.1002/jso.25004↗
  6. Comparison of laparoscopic to open pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma. Co-author DOI 10.1007/s00464-017-5915-0↗
  7. Perioperative and Survival Outcomes Following Neoadjuvant FOLFIRINOX versus Gemcitabine Abraxane in Patients with Pancreatic Adenocarcinoma. Co-author PMID 29950957↗
  8. Characteristics of 10-Year Survivors of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2015.0668↗
  9. Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study. Last author DOI 10.1097/md.0000000000000198↗

Closest collaborators

The 25 strongest of 65 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Richard David Schulick · 8 shared papers, 2014–2024 · strength 0.76
  2. Barish H. Edil · 6 shared papers, 2014–2024 · strength 0.55
  3. Ana Gleisner · 4 shared papers, 2018–2024 · strength 0.45
  4. Marco Del Chiaro · 3 shared papers, 2021–2024 · strength 0.42
  5. Csaba Gajdos · 5 shared papers, 2014–2018 · strength 0.34
  6. Alessandro Paniccia · 5 shared papers, 2014–2019 · strength 0.32
  7. Karyn A. Goodman · 3 shared papers, 2018–2021 · strength 0.29
  8. Wells A. Messersmith · 3 shared papers, 2018–2021 · strength 0.29
  9. Brandon C. Chapman · 3 shared papers, 2018 · strength 0.24
  10. Sara Zakem · 2 shared papers, 2021 · strength 0.21
  11. Adam Christopher Mueller · 2 shared papers, 2021 · strength 0.21
  12. Alexander C. Schulick · 1 shared paper, 2024 · strength 0.21
  13. Hunter B. Moore · 1 shared paper, 2024 · strength 0.21
  14. Robert J. Torphy · 1 shared paper, 2021 · strength 0.12
  15. Michael James Gough · 1 shared paper, 2021 · strength 0.09
  16. David Lagares · 1 shared paper, 2021 · strength 0.09
  17. Miles Piper · 1 shared paper, 2021 · strength 0.09
  18. Ayman J. Oweida · 1 shared paper, 2021 · strength 0.09
  19. Sana D. Karam · 1 shared paper, 2021 · strength 0.09
  20. Kirk Charles Hansen · 1 shared paper, 2021 · strength 0.09
  21. Brian Brauer · 1 shared paper, 2018 · strength 0.08
  22. Andrew H. Ko · 1 shared paper, 2019 · strength 0.06
  23. Matthew H. G. Katz · 1 shared paper, 2019 · strength 0.06
  24. Christoph Tinchon · 1 shared paper, 2019 · strength 0.06
  25. Stephen John Clarke · 1 shared paper, 2019 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.